Dongli Pan | Herpesvirus Infection | Best Researcher Award

Prof. Dr. Dongli Pan | Herpesvirus Infection | Best Researcher Award

Zhejiang University School of Medicine | China

Dr. Prof. Dongli Pan is a distinguished biochemist whose research has significantly advanced the understanding of viral pathogenesis and host-virus interactions. She earned her Ph.D. in Biochemistry from the University of Pennsylvania, Philadelphia (2001–2007), where her dissertation focused on the fast kinetics of tRNA movement on the ribosome during bacterial translation elongation, following a B.S. in Chemistry from Peking University, Beijing (1997–2001). Currently a Professor at the Zhejiang University School of Medicine, Dr. Pan’s major research interests center on the mechanisms of herpes simplex virus (HSV) infection and pathogenesis, HSV-host interactions, and anti-HSV drug development. Her research excellence has been recognized through several competitive national grants, including major projects funded by the National Key R&D Project of China and the National Natural Science Foundation of China, with total funding exceeding several million RMB. Dr. Pan has led and contributed to groundbreaking studies on viral latency, host microRNAs, and innate immune responses to DNA viruses. Before joining Zhejiang University, she conducted postdoctoral research at Harvard Medical School and the University of Pennsylvania, deepening her expertise in molecular virology. In addition to her research, Dr. Pan is a dedicated educator, actively involved in undergraduate and graduate teaching at Zhejiang University and the Zhejiang University–University of Edinburgh Institute, where she organizes and lectures in courses such as Infection 3, Pathogens, and Medical Microbiology and Parasitology, fostering the next generation of biomedical scientists through her bilingual instruction and mentorship.

Profiles: Scopus

Featured Publications

"Inhibitory effect of Alantolactone against varicella-zoster virus in vitro", Virology JournalThis link is disabled., 2025.

"A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing",Nature CommunicationsThis link is disabled., 2025.

"Discovery of Novel Piperazinone-Fused Hydroxypyridinones Inhibiting Herpes Simplex Virus Gene Transcription and Viral Replication", Journal of Medicinal Chemistry, 2025.

"Quantification and analysis of thymidine kinase expression from acyclovir-resistant G-string insertion and deletion mutants in herpes simplex virus-infected cells", J. Virol, 2025.